Biotechnology News and Research

RSS

QLT board approves increase in share repurchase program

QLT Inc. today announced that, subject to regulatory approval, the Board of Directors has approved an increase in the number of common shares that QLT may purchase under its normal course issuer bid over the twelve month period that commenced on November 3, 2009, from 2,731,534 common shares, representing 5% of the outstanding common shares on October 28, 2009, to 4,700,060 common shares, representing 10% of the public float as at that date.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

David H. Fater, CEO of Vicor Technologies, Inc., today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca Trial using its PD2i- algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i- nonlinear algorithm and software.

20 May 2010

UAMS and partners receive $14.7M NIH grant for extension of biomedical research

Biomedical research in Arkansas has received a $14.7 million boost over five years from the National Institutes of Health (NIH) to continue expanding and improving biomedical research in the state.

20 May 2010

Luminex, HTG launch qBead Gene Expression Assay

Luminex Corporation, the worldwide leader in multiplexed solutions, and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA™), today launched a new custom gene expression product, the qBead Gene Expression Assay (qBead Assay). The companies co-developed the product and have signed an exclusive distribution agreement in which Luminex will begin offering it to the research community.

From Luminex 20 May 2010

ImaginAb, GSK CIC conclude two research collaboration agreements

ImaginAb, Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group of Companies) have concluded two research collaboration agreements around a clinical therapeutic antibody asset currently under development by GSK in the field of oncology.

20 May 2010

Curis announces inclusion in NASDAQ Biotechnology Index

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.

19 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

Experimental evolution used to develop new strains of bacteria for use as probiotic substances

When the forces of evolution took over an experimental strain of bacteria, it derailed an experiment Duke and NC State researchers thought they were conducting, but led to something much more profound instead.

19 May 2010

Promosome signs technology license and partnership agreement with Recopharma AB of Stockholm

Promosome LLC, a biotechnology company uniquely dedicated to the development of technologies related to the regulation of protein synthesis through translation initiation, today announced the signing of a technology license and partnership agreement with Recopharma AB of Stockholm, Sweden. Recopharma is a recognized leader in the research and development of therapeutic recombinant mucin-type fusion proteins.

19 May 2010

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.

19 May 2010

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Four new projects, announced today, will develop biological methods that offer a new approach to antibiotic production, power generation for extremely small mechanical components, new classes of medicines and innovative techniques to study cell biology.

19 May 2010

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Discovery Laboratories, Inc. announces today that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) has been completed, having met all pre-specified acceptance criteria.

19 May 2010

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.

19 May 2010

i3 completes acquisition of ChinaGate

i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

Molecular Devices' foundational planar patch-clamp patent upheld by European Patent Office

Molecular Devices today announced that European Patent Office (EPO) has upheld Molecular Devices foundational planar patch-clamp patent (EP No 1 040 349 B1). The board will issue a written decision to this effect in the near future. The ruling will be the final determination of the EPO and cannot be appealed.

19 May 2010

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Oncolytics Biotech Inc. announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

19 May 2010

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis."

19 May 2010

FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II

Illumina, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the VeraCode® Genotyping Test for Factor V (Leiden) and Factor II (Prothrombin).

From Illumina, Inc. 19 May 2010

Biotechnology News and Research

QLT board approves increase in share repurchase program

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

UAMS and partners receive $14.7M NIH grant for extension of biomedical research

Luminex, HTG launch qBead Gene Expression Assay

ImaginAb, GSK CIC conclude two research collaboration agreements

Curis announces inclusion in NASDAQ Biotechnology Index

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Experimental evolution used to develop new strains of bacteria for use as probiotic substances

Promosome signs technology license and partnership agreement with Recopharma AB of Stockholm

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

i3 completes acquisition of ChinaGate

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Molecular Devices' foundational planar patch-clamp patent upheld by European Patent Office

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News